Education
About Us
Working with TipRanks
Follow Us
MEDX - AI Analysis
Top Page
Horizon Kinetics Medical ETF (MEDX)
Rating:62Neutral
Price Target:
$34.00
Positive Factors
Strong Top Holdings
Several key holdings, such as Ionis Pharmaceuticals and Alnylam Pharma, have delivered strong year-to-date performance, boosting the ETF's returns.
Sector Focus on Health Care
The ETF's concentration in the health care sector provides exposure to a historically resilient and growing industry.
Steady Performance
The ETF has shown consistent positive returns across one-month, three-month, and year-to-date periods, indicating solid momentum.
Negative Factors
High Expense Ratio
The ETF charges a relatively high expense ratio compared to many other funds, which can eat into investor returns over time.
Over-Concentration in Health Care
With nearly all assets allocated to the health care sector, the ETF is highly exposed to risks specific to this industry.
Limited Geographic Diversification
The ETF is heavily weighted toward U.S. companies, offering little exposure to international markets.
MEDX vs. SPDR S&P 500 ETF (SPY)
AUM17.77M
RegionGlobal
Expense Ratio0.85%
Beta0.65
IssuerHorizon
Inception DateJan 30, 2023
Dividend Yield1.62%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume802
30 Day Avg. Volume1,137
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
36.93Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering33
MEDX Summary
The Horizon Kinetics Medical ETF (MEDX) is a fund that focuses on the health care sector, including biotechnology, pharmaceuticals, medical devices, and health care providers. It holds shares in well-known companies like Eli Lilly and AbbVie, which are leaders in medical innovation. This ETF is ideal for investors who want to benefit from the growth potential of the health care industry, driven by advancements in medical research and an aging population. However, new investors should be aware that the fund’s performance is heavily tied to the health care sector, which can be affected by changes in regulations or market conditions.
How much will it cost me?The Horizon Kinetics Medical ETF (MEDX) has an expense ratio of 0.85%, meaning you’ll pay $8.50 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on specialized health care investments that require more research and expertise.
What would affect this ETF?The Horizon Kinetics Medical ETF (MEDX) could benefit from ongoing advancements in medical research, an aging global population driving demand for health care, and increased health awareness globally. However, challenges such as regulatory changes, patent expirations for major pharmaceutical companies, or economic downturns impacting health care spending could negatively affect its performance. With top holdings like Eli Lilly and AbbVie, the ETF's success is closely tied to the innovation and market conditions within the health care sector.
MEDX Top 10 Holdings
The Horizon Kinetics Medical ETF (MEDX) is leaning heavily on health care giants like Eli Lilly and AbbVie, both of which have shown steady growth thanks to strong earnings and strategic investments. Novartis and AstraZeneca are also rising stars, benefiting from robust profitability and shareholder-friendly moves. However, Bristol-Myers Squibb is lagging, weighed down by technical weakness and debt concerns, which slightly dampens the fund’s overall momentum. With a clear focus on the health care sector and global exposure, MEDX offers a concentrated bet on innovation and resilience in medical advancements.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 14.85% | $2.64M | $769.97B | -3.93% | 70 Outperform | |
| AbbVie | 9.42% | $1.67M | $397.72B | 11.73% | 64 Neutral | |
| Novartis | 6.39% | $1.13M | $234.55B | 10.82% | 73 Outperform | |
| Alnylam Pharma | 6.36% | $1.13M | $63.13B | 71.09% | 60 Neutral | |
| AstraZeneca | 5.11% | $908.21K | $257.12B | 12.91% | 77 Outperform | |
| Ionis Pharmaceuticals | 4.95% | $879.31K | $11.46B | 83.09% | 57 Neutral | |
| Johnson & Johnson | 4.84% | $860.25K | $449.57B | 16.18% | 78 Outperform | |
| Bristol-Myers Squibb | 3.87% | $687.35K | $86.71B | -19.10% | 66 Neutral | |
| Alkermes | 3.85% | $684.05K | $5.19B | 19.54% | 74 Outperform | |
| Amgen | 3.71% | $660.12K | $157.08B | -7.53% | 70 Outperform |
MEDX Technical Analysis
Positive
―
Price Trends
30.15
Positive
28.80
Positive
27.82
Positive
Market Momentum
0.34
Positive
49.37
Neutral
9.06
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MEDX, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 31.53, equal to the 50-day MA of 30.15, and equal to the 200-day MA of 27.82, indicating a neutral trend. The MACD of 0.34 indicates Positive momentum. The RSI at 49.37 is Neutral, neither overbought nor oversold. The STOCH value of 9.06 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MEDX.
MEDX Peer Comparison
Comparison Results
Performance Comparison
MEDX
Horizon Kinetics Medical ETF
30.94
1.93
6.65%
FMED
Fidelity Disruptive Medicine ETF
―
―
―
MEDI
Harbor Health Care ETF
―
―
―
TMED
T. Rowe Price Health Care ETF
―
―
―
JDOC
JPMorgan Healthcare Leaders ETF
―
―
―
BMED
Future Health ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents